Different health claims can be used with Actilight®. Visit the Scientific evidence section to learn about the proven benefits.
According to the new European regulation*, five health claims related to FOS from sucrose under Art 13.1 have been submitted for evaluation by EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) through different member states in 2008:
774/779/781 - Decreasing potentially pathogenic gastro-intestinal microorganisms
775 - Change in short-chain fatty acid (SCFA) production and pH in the gastro-intestinal tract
777 - Increase in calcium and/or magnesium absorption
778 - Reduction of gastro-intestinal discomfort
805 - Maintenance of normal LDL-cholesterol and triglycerides concentrations in blood
The panel considered that Fructo-oligosaccharides (FOS) from sucrose are sufficiently characterised. Nevertheless, on the basis of the scientific data presented, the Panel concludes that a cause and effect relationship has not been established between consumption of FOS from sucrose and the following beneficial physiological effects.
The scientific opinion has been published in the EFSA Journal 2011 under numbers 2222 and 2223. All Health claims may remain on the market until mid 2012 (i.e. for 6 months after the adoption of a decision by the European Commission).
Nevertheless, we remain confident for the future, considering that the dossiers were filed end of 2008 under unclear conditions, whereas the EFSA has since clarified its expectations in the guideline published in April 2011 on "Gut and immune function claims" and considering the recent arrival of new clinical studies that support existing scientific knowledge.
Tereos Syral - Beghin Meiji intend to submit new dossiers under Art. 13.5 based on new scientific evidence.
Click here to download Tereos Syral Communication on the use of health claims related to Fructo-oligosaccharides (FOS) from sucrose (14 August 2011)